Metotrexato Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the formation of tetrahydrofolate needed for DNA synthesis. This interruption reduces the replication of rapidly dividing cells, such as immune cells involved in inflammation and cancer cells, thereby decreasing disease activity.

The exact dose and schedule of Metotrexato Accord are determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Healthcare providers tailor the regimen to achieve optimal efficacy while minimizing toxicity.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is the most widely used folate antagonist and is often preferred for its extensive clinical experience, multiple administration routes, and cost‑effectiveness. Alternatives such as pemetrexed have different toxicity profiles and are typically reserved for specific cancer types, whereas methotrexate remains the first‑line choice for many autoimmune and hematologic conditions.

Metotrexato Accord should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid freezing or exposing it to extreme temperatures.

The drug is supplied as a sterile solution for intra‑arterial, intramuscular or intrathecal injection, depending on the clinical indication. Administration is performed by qualified healthcare professionals under aseptic conditions, with dosing intervals and volumes determined by the treating physician.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, acute renal failure, and rare cases of pancytopenia. Patients should be monitored regularly for signs of organ dysfunction and counseled to report any unusual symptoms promptly.

Methotrexate is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate or its excipients, and those receiving live vaccines. Clinicians should also exercise caution in patients with pre‑existing blood dyscrasias or pulmonary disease.